¼¼°èÀÇ ¼Ò È£Èí±â Áúȯ Ä¡·áÁ¦ ½ÃÀå
Bovine Respiratory Disease Treatment
»óǰÄÚµå : 1563910
¸®¼­Ä¡»ç : Global Industry Analysts, Inc.
¹ßÇàÀÏ : 2024³â 09¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 179 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 5,850 £Ü 8,464,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 17,550 £Ü 25,393,000
PDF (Global License to Company and its Fully-owned Subsidiaries) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμâ´Â °¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


Çѱ۸ñÂ÷

¼Ò È£Èí±â Áúȯ Ä¡·áÁ¦ ¼¼°è ½ÃÀå ±Ô¸ð´Â 2030³â±îÁö 34¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»ó

2023³â 22¾ï ´Þ·¯·Î ÃßÁ¤µÇ´Â ¼Ò È£Èí±â Áúȯ Ä¡·áÁ¦ ¼¼°è ½ÃÀåÀº 2023-2030³âÀÇ ºÐ¼® ±â°£ µ¿¾È ¿¬Æò±Õ 6.4% ¼ºÀåÇÏ¿© 2030³â¿¡´Â 34¾ï ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. º» º¸°í¼­¿¡¼­ ºÐ¼®ÇÑ ºÎ¹® Áß ÇϳªÀÎ ¹é½ÅÀº CAGR 7.8%¸¦ ±â·ÏÇÏ¿© ºÐ¼® ±â°£ Á¾·á ½ÃÁ¡¿¡ 14¾ï ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. Ç×»ýÁ¦ ºÐ¾ßÀÇ ¼ºÀå·üÀº ºÐ¼® ±â°£ µ¿¾È CAGR 6.5%·Î ÃßÁ¤µË´Ï´Ù.

¹Ì±¹ ½ÃÀåÀº 5¾ï 7,810¸¸ ´Þ·¯·Î ÃßÁ¤, Áß±¹Àº CAGR 9.7%·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»ó

¹Ì±¹ÀÇ ¼Ò È£Èí±â Áúȯ Ä¡·á ½ÃÀåÀº 2023³â 5¾ï 7,810¸¸ ´Þ·¯·Î ÃßÁ¤µË´Ï´Ù. ¼¼°è 2À§ÀÇ °æÁ¦ ´ë±¹ÀÎ Áß±¹Àº 2023-2030³â 9.7%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î 2030³â±îÁö 8¾ï 8,100¸¸ ´Þ·¯ ±Ô¸ð¿¡ µµ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ´Ù¸¥ ÁÖ¸ñÇÒ ¸¸ÇÑ Áö¿ª ½ÃÀåÀ¸·Î´Â ÀϺ»°ú ij³ª´Ù°¡ ÀÖÀ¸¸ç, ºÐ¼® ±â°£ µ¿¾È °¢°¢ 3.1%¿Í 5.8%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)À» ³ªÅ¸³¾ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. À¯·´¿¡¼­´Â µ¶ÀÏÀÌ 3.9%ÀÇ ¿¬Æò±Õ º¹ÇÕ ¼ºÀå·ü(CAGR)·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.

¼¼°è ¼Ò È£Èí±â Áúȯ Ä¡·áÁ¦ ½ÃÀå - ÁÖ¿ä µ¿Çâ ¹× ÃËÁø¿äÀÎ Á¤¸®

¼Ò È£Èí±â ÁúȯÀ̶õ ¹«¾ùÀΰ¡?

¼Ò È£Èí±â Áúȯ(Bovine Respiratory Disease: BRD)Àº Àü ¼¼°è ¼Ò, ƯÈ÷ À°¿ì¿Í Á¥¼Ò¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡´Â ½É°¢ÇÑ °Ç°­ ¹®Á¦ÀÔ´Ï´Ù. ÃÖ±Ù¿¡ ¼ö¼ÛµÈ ¼Ò¿¡°Ô ÀÚÁÖ ¹ß»ýÇϱ⠶§¹®¿¡ '¼ö¼Û¿­'À̶ó°í ºÒ¸®Áö¸¸, ±× ¿µÇâÀº ÈξÀ ´õ ±¤¹üÀ§ÇÏ¸ç ¸ðµç ¿¬·É°ú À¯ÇüÀÇ ¼Ò¿¡°Ô ¿µÇâÀ» ¹ÌĨ´Ï´Ù. ÀÌ Áúº´Àº º¹ÀâÇÏ°í ´ÙÀÎÀÚÀûÀÎ º´Å·Π¿î¼Û, È¥Ç÷, ȯ°æ º¯È­ µî ´Ù¾çÇÑ ½ºÆ®·¹½º ¿äÀΰú ¹ÙÀÌ·¯½º, ¹ÚÅ׸®¾Æ, ¸¶ÀÌÄÚÇöóÁ µî °¨¿° ¿äÀÎÀÇ »óÈ£ ÀÛ¿ë¿¡ ÀÇÇØ ¹ß»ýÇϸç, BRD´Â üÁß Áõ°¡ °¨¼Ò, »ç·á ¿ä±¸·® Áõ°¡, Æó»çÀ² Áõ°¡, Ä¡·á ¹× ¿¹¹æ Á¶Ä¡ ºñ¿ëÀ¸·Î ÀÎÇØ ½É°¢ÇÑ °æÁ¦Àû ¼Õ½ÇÀ» ÃÊ·¡ÇÏ´Â °ÍÀ¸·Î À¯¸íÇÕ´Ï´Ù. ¼Õ½ÇÀ» À¯¹ßÇÏ´Â °ÍÀ¸·Î À¯¸íÇÕ´Ï´Ù. ¶ÇÇÑ µ¿¹° º¹Áö¿¡µµ Å« ¿µÇâÀ» ¹ÌÄ¡±â ¶§¹®¿¡ º¸´Ù È¿°úÀûÀ̰í ÀεµÀûÀÎ Ä¡·á¹ý¿¡ ´ëÇÑ ¿ä±¸°¡ Áõ°¡Çϰí ÀÖÀ¸¸ç, BRD´Â º¹ÀâÇÏ°í ´Ù¸éÀûÀ̱⠶§¹®¿¡ ±× Ä¡·á´Â ¼öÀÇÇÐ ¹× °¡Ãà °ü¸®ÀÇ Áß¿äÇÑ ÃÊÁ¡ÀÌ µÇ°í ÀÖ½À´Ï´Ù.

¼Ò È£Èí±â ÁúȯÀÇ ÇöÀç Ä¡·á Àü·«Àº ¾î¶»°Ô ÁøÈ­Çϰí Àִ°¡?

Áö³­ ¸î ³âµ¿¾È ¼Ò È£Èí±â ÁúȯÀÇ Ä¡·á¿¡ Å« ÁøÀüÀÌ ÀÖ¾ú½À´Ï´Ù. Áúº´¿¡ ´ëÇÑ º´¸®ÇÐÀû ÀÌÇØ°¡ ±í¾îÁö°í »õ·Î¿î Ä¡·á¹ýÀÌ °³¹ßµÇ¾ú±â ¶§¹®ÀÔ´Ï´Ù. ±âÁ¸ÀÇ Ä¡·á Àü·«Àº ¿­°ú ÅëÁõÀ» ¾ïÁ¦ÇÏ´Â Ç׿°ÁõÁ¦¿Í °°Àº ÁöÁö ¿ä¹ý°ú ÇÔ²² Áúº´ÀÇ ¼¼±Õ ¼ººÐÀ» Ç¥ÀûÀ¸·Î ÇÏ´Â ±¤¹üÀ§ Ç×»ýÁ¦¸¦ »ç¿ëÇÏ´Â °ÍÀÌ ÀϹÝÀûÀ̾ú½À´Ï´Ù. ±×·¯³ª Ç×»ýÁ¦ ³»¼º ¹× ÀÌ·¯ÇÑ Ä¡·á¹ýÀÇ È¿°ú¿¡ ´ëÇÑ ¿ì·Á·Î ÀÎÇØ º¸´Ù Ç¥ÀûÈ­µÈ Á¢±Ù¹ýÀÌ ¸ð»öµÇ°í ÀÖ½À´Ï´Ù. »õ·Î¿î Ä¡·á¹ýÀº Áø´Ü µµ±¸¸¦ »ç¿ëÇÏ¿© ƯÁ¤ BRD »ç·Ê¿¡ °ü¿©Çϴ ƯÁ¤ º´¿øÃ¼¸¦ ½Äº°ÇÏ°í º¸´Ù ¸ÂÃãÈ­µÈ Ä¡·á ÇÁ·ÎÅäÄÝÀ» °¡´ÉÇÏ°Ô ÇÏ´Â Á¤¹ÐÀÇ·á¿¡ Á¡Á¡ ´õ ÃÊÁ¡À» ¸ÂÃß¾ú½À´Ï´Ù. ¶ÇÇÑ, µ¿¹°ÀÇ ¸é¿ª ¹ÝÀÀÀ» °­È­ÇÏ¿© °¨¿°À» º¸´Ù È¿°úÀûÀ¸·Î ÅðÄ¡ÇÏ´Â °ÍÀ» ¸ñÇ¥·Î ÇÏ´Â ¸é¿ª Á¶Àý ¿ä¹ý¿¡ ´ëÇÑ °ü½Éµµ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹ßÀüÀº ȸº¹·üÀ» Çâ»ó½Ãų »Ó¸¸ ¾Æ´Ï¶ó Ç×»ýÁ¦ °ú´Ù »ç¿ëÀ¸·Î ÀÎÇÑ À§ÇèÀ» ÁÙÀÏ ¼ö ÀÖ´Â º¸´Ù Áö¼Ó °¡´ÉÇϰí È¿°úÀûÀÎ Ä¡·á ¿ä¹ýÀ¸·ÎÀÇ ÀüȯÀ» ÀǹÌÇÕ´Ï´Ù.

¼Ò È£Èí±â Áúȯ ¿¹¹æÀÇ »õ·Î¿î µ¿ÇâÀº ¹«¾ùÀΰ¡?

¼Ò È£Èí±â ÁúȯÀÇ ¿¹¹æÀº Áß¿äÇÑ ºÐ¾ß°¡ µÇ¾úÀ¸¸ç, ¾÷°è¿¡¼­´Â ¹ßº´ ÈÄ Ä¡·áÇÏ´Â °Íº¸´Ù ¿¹¹æÇÏ´Â °ÍÀÌ ºñ¿ë È¿À²ÀûÀ̰í À¯ÀÍÇÑ °ÍÀ¸·Î Àνĵǰí ÀÖ½À´Ï´Ù. ¹é½Å Á¢Á¾ ÇÁ·Î±×·¥Àº BRD ¿¹¹æÀÇ ±âÃÊÀ̸ç, °¡Àå ÈçÇÑ ¹ÙÀÌ·¯½º ¹× ¼¼±Õ¼º º´¿øÃ¼¸¦ Ç¥ÀûÀ¸·Î ÇÏ´Â ¹é½ÅÀ» »ç¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. º¸´Ù È¿°úÀûÀÎ ¹é½ÅÀÇ °³¹ßÀº ºñ°­ ½ºÇÁ·¹ÀÌ¿Í °°Àº »õ·Î¿î Åõ¿© ¹æ¹ýÀ» Æ÷ÇÔÇÏ¿© ¾÷°è¿¡¼­ ÁøÇàÁßÀÎ Ãß¼¼ÀÔ´Ï´Ù. ¶Ç ´Ù¸¥ Áß¿äÇÑ Æ®·»µå´Â µ¥ÀÌÅÍ ºÐ¼®, ¼¾¼­ ¹× ¸ð´ÏÅ͸µ ½Ã½ºÅÛÀ» Ȱ¿ëÇÏ¿© À§Çè¿¡ óÇÑ °¡ÃàÀ» Á¶±â¿¡ ½Äº°Çϰí Áúº´ÀÌ È®»êµÇ±â Àü¿¡ ¿¹¹æ Á¶Ä¡¸¦ ÃëÇÒ ¼ö ÀÖ´Â Á¤¹Ð Ãà»ê ±â¼úÀÇ È°¿ëÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ±â¼úÀ» ÅëÇØ °¡Ã౺À» Áö¼ÓÀûÀ¸·Î ¸ð´ÏÅ͸µÇϰí Á¶±â °³ÀÔÀ» ÅëÇØ BRD ¹ß»ýÀ» Å©°Ô ÁÙÀÏ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ¿î¼Û Áß ½ºÆ®·¹½º °¨¼Ò, ¿µ¾ç ÃÖÀûÈ­, ÀûÀýÇÑ »çÀ° ȯ°æ È®º¸ µî Àü¹ÝÀûÀÎ °¡Ãà °ü¸®ÀÇ °³¼±ÀÌ °­Á¶µÇ°í ÀÖÀ¸¸ç, ÀÌ ¸ðµç °ÍÀÌ Áúº´ ¹ß»ý À§ÇèÀ» ³·Ãß´Â µ¥ ±â¿©Çϰí ÀÖ½À´Ï´Ù.

¼Ò È£Èí±â Áúȯ Ä¡·á ½ÃÀåÀÇ ¼ºÀå ÃËÁø¿äÀÎÀº ¹«¾ùÀΰ¡?

¼Ò È£Èí±â Áúȯ Ä¡·á ½ÃÀåÀÇ ¼ºÀåÀº ±â¼ú ¹ßÀü, ÃÖÁ¾ ¿ëµµÀÇ º¯È­, ¼ÒºñÀÚ ÇൿÀÇ ÁøÈ­¿Í Á÷Á¢ÀûÀ¸·Î °ü·ÃµÈ ¸î °¡Áö ¿äÀο¡ ÀÇÇØ ÁÖµµµÇ°í ÀÖ½À´Ï´Ù. ÁÖ¿ä ÃËÁø¿äÀÎ Áß Çϳª´Â µ¿¹° ÀÇ·á ºÐ¾ß¿¡¼­ Á¤¹ÐÀÇ·áÀÇ Ã¤ÅÃÀÌ Áõ°¡ÇÔ¿¡ µû¶ó º¸´Ù Á¤È®Çϰí È¿°úÀûÀÎ Ä¡·á°¡ °¡´ÉÇØÁ® ȸº¹·ü Çâ»ó°ú »ç¸Á·ü °¨¼Ò·Î À̾îÁö°í ÀÖ´Ù´Â Á¡ÀÔ´Ï´Ù. °¡Ãà »çÀ°µÎ¼ö Áõ°¡¿Í ÇÔ²² È¿°úÀûÀÎ BRD Ä¡·á ¿É¼Ç¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ƯÈ÷ ½ÅÈï±¹ ½ÃÀå¿¡¼­ Ãà»ê¾÷ÀÌ È®´ëµÇ°í ÀÖ´Â °Íµµ ½ÃÀå ¼ºÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù. ¶ÇÇÑ, ÀεµÀûÀ̰í Áö¼Ó °¡´ÉÇÑ Á¶°Ç¿¡¼­ »ý»êµÈ À°·ù ¹× À¯Á¦Ç°¿¡ ´ëÇÑ ¼ÒºñÀÚ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó Ãà»ê ¾÷üµéÀº BRD¿Í °°Àº Áúº´¿¡ ´ëÇØ º¸´Ù È¿°úÀûÀ̰í À±¸®ÀûÀÎ Ä¡·á ÇÁ·ÎÅäÄÝÀ» äÅÃÇϵµ·Ï ¿ä±¸¹Þ°í ÀÖ½À´Ï´Ù. ¶ÇÇÑ, °¡Ãà¿¡ ´ëÇÑ Ç×»ýÁ¦ »ç¿ë °¨¼Ò¿¡ ´ëÇÑ ±ÔÁ¦ ¾Ð·ÂÀ¸·Î ÀÎÇØ ¸é¿ª Á¶Àý ¿ä¹ýÀ̳ª Ç¥Àû Ç×±ÕÁ¦ Ä¡·á¿Í °°Àº ´ëü Ä¡·á¹ýÀÇ °³¹ß ¹× äÅÃÀÌ °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù. ¸¶Áö¸·À¸·Î, Áø´Ü ±â¼úÀÇ ¹ßÀüÀ¸·Î ¼öÀǻ簡 BRD¸¦ ½Å¼ÓÇϰí Á¤È®ÇÏ°Ô Áø´ÜÇÒ ¼ö ÀÖ°Ô µÇ¾î º¸´Ù ½Å¼ÓÇϰí È¿°úÀûÀÎ Ä¡·á°¡ °¡´ÉÇØÁü¿¡ µû¶ó ½ÃÀå È®´ë°¡ ´õ¿í °¡¼ÓÈ­µÇ°í ÀÖ½À´Ï´Ù.

Á¶»ç ´ë»ó ±â¾÷ ¿¹½Ã(ÁÖ¸ñÇÒ ¸¸ÇÑ 12°³ ±â¾÷)

  • Bayer AG
  • Bimeda Group
  • Boehringer Ingelheim International GmbH
  • Ceva Sante Animale
  • Elanco
  • Merck & Co.
  • Vetoquinol S.A.
  • Virbac Group
  • Zoetis Services LLC

    ¸ñÂ÷

    Á¦1Àå Á¶»ç ¹æ¹ý

    Á¦2Àå ÁÖ¿ä ¿ä¾à

    • ½ÃÀå °³¿ä
    • ÁÖ¿ä ±â¾÷
    • ½ÃÀå µ¿Çâ°ú ÃËÁø¿äÀÎ
    • ¼¼°è ½ÃÀå Àü¸Á

    Á¦3Àå ½ÃÀå ºÐ¼®

    • ¹Ì±¹
    • ij³ª´Ù
    • ÀϺ»
    • Áß±¹
    • À¯·´
    • ÇÁ¶û½º
    • µ¶ÀÏ
    • ÀÌÅ»¸®¾Æ
    • ¿µ±¹
    • ½ºÆäÀÎ
    • ·¯½Ã¾Æ
    • ±âŸ À¯·´
    • ¾Æ½Ã¾ÆÅÂÆò¾ç
    • È£ÁÖ
    • Àεµ
    • Çѱ¹
    • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
    • ¶óƾ¾Æ¸Þ¸®Ä«
    • ¾Æ¸£ÇîÆ¼³ª
    • ºê¶óÁú
    • ¸ß½ÃÄÚ
    • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
    • Áßµ¿
    • À̶õ
    • À̽º¶ó¿¤
    • »ç¿ìµð¾Æ¶óºñ¾Æ
    • ¾Æ¶ø¿¡¹Ì¸®Æ®(UAE)
    • ±âŸ Áßµ¿
    • ¾ÆÇÁ¸®Ä«

    Á¦4Àå °æÀï

    LSH
  • ¿µ¹® ¸ñÂ÷

    ¿µ¹®¸ñÂ÷

    Global Bovine Respiratory Disease Treatment Market to Reach US$3.4 Billion by 2030

    The global market for Bovine Respiratory Disease Treatment estimated at US$2.2 Billion in the year 2023, is expected to reach US$3.4 Billion by 2030, growing at a CAGR of 6.4% over the analysis period 2023-2030. Vaccines, one of the segments analyzed in the report, is expected to record a 7.8% CAGR and reach US$1.4 Billion by the end of the analysis period. Growth in the Antibiotics segment is estimated at 6.5% CAGR over the analysis period.

    The U.S. Market is Estimated at US$578.1 Million While China is Forecast to Grow at 9.7% CAGR

    The Bovine Respiratory Disease Treatment market in the U.S. is estimated at US$578.1 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$808.1 Million by the year 2030 trailing a CAGR of 9.7% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.1% and 5.8% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 3.9% CAGR.

    Global Bovine Respiratory Disease Treatment Market - Key Trends and Drivers Summarized

    What Is Bovine Respiratory Disease and Why Is It a Major Concern?

    Bovine Respiratory Disease (BRD) is a significant health issue affecting cattle populations worldwide, particularly in beef and dairy herds. It is often referred to as "shipping fever" because it commonly occurs in cattle that have been recently transported, but its impact is far broader, affecting all ages and types of cattle. The disease is a complex, multifactorial condition that results from the interaction of various stress factors—such as transportation, co-mingling, and environmental changes—with infectious agents including viruses, bacteria, and mycoplasma. BRD is notorious for causing severe economic losses due to decreased weight gain, higher feed conversion rates, increased mortality, and the cost of treatment and preventive measures. It also has a substantial impact on animal welfare, leading to a push for more effective and humane treatment options. The complexity and multifaceted nature of BRD make its treatment a critical focus area in veterinary medicine and livestock management.

    How Are Current Treatment Strategies Evolving for Bovine Respiratory Disease?

    In recent years, there have been significant advancements in the treatment of Bovine Respiratory Disease, driven by a better understanding of the disease's pathology and the development of new therapeutic interventions. Traditional treatment strategies have typically involved the use of broad-spectrum antibiotics to target the bacterial component of the disease, alongside supportive care such as anti-inflammatory drugs to reduce fever and pain. However, concerns about antibiotic resistance and the efficacy of such treatments have led to the exploration of more targeted approaches. Newer therapies are increasingly focused on precision medicine, which involves the use of diagnostic tools to identify the specific pathogens involved in a particular case of BRD, allowing for more tailored treatment protocols. Additionally, there has been a growing interest in immunomodulatory therapies that aim to boost the animal’s immune response to fight off the infection more effectively. These advancements represent a shift towards more sustainable and effective treatment regimens that not only improve recovery rates but also help mitigate the risks associated with antibiotic overuse.

    What Are the Emerging Trends in Bovine Respiratory Disease Prevention?

    The prevention of Bovine Respiratory Disease has become a key area of focus, as the industry recognizes that preventing the disease is more cost-effective and beneficial than treating it after it occurs. Vaccination programs are a cornerstone of BRD prevention, with vaccines available that target the most common viral and bacterial pathogens. The development of more effective vaccines, including those that can be administered through novel delivery methods such as intranasal sprays, is an ongoing trend in the industry. Another significant trend is the use of precision livestock farming techniques, which leverage data analytics, sensors, and monitoring systems to identify at-risk animals early and take preventive measures before the disease can spread. These technologies allow for the continuous monitoring of cattle herds, enabling early intervention that can significantly reduce the incidence of BRD. Additionally, there is a growing emphasis on improving overall herd management practices, such as reducing stress during transportation, optimizing nutrition, and ensuring proper housing conditions, all of which contribute to a lower risk of disease outbreaks.

    What Is Driving the Growth of the Bovine Respiratory Disease Treatment Market?

    The growth in the Bovine Respiratory Disease treatment market is driven by several factors directly related to technological advancements, changing end-use practices, and evolving consumer behavior. One of the key drivers is the increasing adoption of precision medicine in veterinary care, which allows for more accurate and effective treatments, leading to higher recovery rates and reduced mortality. The expansion of livestock farming, particularly in developing regions, is also fueling market growth, as the demand for effective BRD treatment options rises in tandem with the growth of the cattle population. Moreover, there is a growing consumer demand for meat and dairy products produced under humane and sustainable conditions, which has pushed livestock producers to adopt more effective and ethical treatment protocols for diseases like BRD. Regulatory pressures to reduce antibiotic use in livestock have also accelerated the development and adoption of alternative treatment methods, such as immunomodulatory therapies and targeted antimicrobial therapies. Finally, advancements in diagnostic technologies are making it easier for veterinarians to quickly and accurately diagnose BRD, leading to more timely and effective treatments, further driving the market's expansion.

    Select Competitors (Total 12 Featured) -

    TABLE OF CONTENTS

    I. METHODOLOGY

    II. EXECUTIVE SUMMARY

    III. MARKET ANALYSIS

    IV. COMPETITION

    (ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
    ¨Ï Copyright Global Information, Inc. All rights reserved.
    PC¹öÀü º¸±â